Don’t miss this opportunity to join global experts, researchers and clinicians dedicated to advancing mastocytosis care and research. Registration is free for all attendees, but spaces are limited, so secure your place today!
Explore the latest research and innovations in mastocytosis care.
Learn from renowned experts leading advancements in the field.
Engage in thought-provoking discussions, case study reviews and workshops.
Connect with global leaders and peers in a collaborative environment.
The European Competence Network on Mastocytosis (ECNM) is a collaborative network established to improve the diagnosis, treatment and understanding of mastocytosis, a rare disease characterised by the accumulation of mast cells in various tissues.
Explore the latest research and innovations in mastocytosis care.
Explore the latest research and innovations in mastocytosis care.
Connect with global leaders and peers in a collaborative environment.
Explore the latest research and innovations in mastocytosis care.
We look forward to receiving your abstracts and to welcoming you to Mannheim for this landmark event in the mastocytosis community.
Registration and Welcome Coffee
Welcome and Introduction
Juliana Schwaab
Andreas Reiter
Wolf-Karsten Hofmann
Status of the ECNM in 2026 und future perspectives
Peter Valent
Frank Siebenhaar
Researcher of the Year
Introduction by Frank Siebenhaar
Peter Valent
Lecture: Clinical implications of co-existing IgE-dependent allergies in patients with mastocytosis by Patrizia Bonadonna
Session 1: The pathologists view on SM and AHN
Chairs: Michael Doubek, Karl Sotlar
Diagnosis and subtyping of AHN by Karl Sotlar
Bringing together WHO and ICC by Tracy I. George
My most challenging cases by Hans-Peter Horny
Discussion
Coffee break
Session 2: Diagnostic challenges
Chairs: Friederike Wortmann, Saskia Klein
Serum tryptase: pitfalls and perspectives by Lawrence B. Schwartz
MCAD and HαT: definitions, diagnostic criteria and prognostic variables by Peter Valent
HαT in the Clinic: Risk, symptoms, and therapeutic implications by Jonathan J. Lyons
KIT D816V, cytogenetics and additional somatic mutations by Nicholas C.P. Cross
Discussion
Session 3: Genetic complexity of SM and AHN
Chairs: Julien Rossignol, Tracy I. George
Genetic pattens and lineage involvement in SM and AHN by Alberto Orfao
How additional mutations shape diagnosis and prognosis in mastocytosis by Johannes Lübke
Novel markers, targets and technologies in SM and AHN by Gregor Hörmann
Discussion
Summary of day 1 and announcements
Peter Valent
Reception at Rheinterassen, Rheinpromenade 15, 68163 Mannheim
Sponsored by Cogent
Registration and Welcome
Session 4: ECNM registry projects part 1
Chairs: Peter Valent, Wolfgang R. Sperr
Overview of the Registry and the Status of Project Waves by Wolfgang R. Sperr
Overview of Registry Projects W1-W9 by Peter Valent
PR1: analysis of various age groups by Marc Emmenegger
PR7: Spectrum of mediator-related symptoms by Massimo Triggiani
PR8: Treatment of patients with mastocytosis by Chiara Elena & Wolfgang R. Sperr
PR12: Course and prognosis in SSM by Matthias Christen
PR15: Clinical features and course in various forms of ASM by Khalid Shoumariyeh
PR28: Clinical impact of reported co-morbidities by Olivier Hermine, Julien Rossignol & Michel Arock
Discussion
Coffee break
Session 4: ECNM registry projects part 2
Chairs: Peter Valent, Wolfgang R. Sperr
PR30: Impact of monocytes in mastocytosis by Friederike Wortmann
PR31: prognostic impact of inflammation parameters by Michael Makris & Fotios Koliofotis
PR32: Impact of region and referral site by Rebekka Linhart
PR37: Impact of additional mutations in SM on OS and PFS by Michael Doubek
PR38: Impact of specific allergies in mastocytosis by Hanneke Oude Elberink
PR40: WHO versus ICC classifications in mastocytosis by Massimiliano Bonifacio
PR46: Validation of the IPSM with an updated data set by Wolfgang R. Sperr
New projects, proposals and project waves 2026/2027 by Peter Valent
Group photo
Lunch break
(closed session of the ECNM registry steering committee)
Session 5: Anaphylaxis and MCAS
Clive Grattan, Deborah Christen
Allergies and intolerance in mastocytosis: myth, mechanisms and triggers Hanneke by Oude Elberink
Hymenoptera venom allergy: risk stratification and management by Marek Niedoszytko
Concepts, controversies and criteria around MCAD by Theo Gulen
MCAD: clinical reality and unmet needs by Mariana Castells
Discussion
Session 6: Organ involvement and paediatry
Chairs: Melody C. Carter, Vito Sabato
Cutaneous involvement in SM: clinical manifestations and suitability as response marker to treatment by Karin Hartmann
Differential diagnosis to cutaneous lesions in CM and SM: diagnostic measures, assays and algorithms by Clive Grattan
Diagnosis and management of pediatric mastocytosis: the challenge for dermatologist and paediatrician by Magdalena Lange
Advanced mastocytosis in children: diagnosis and therapy by Melody C. Carter
Osteopathy in SM: diagnosis and new treatment options by Massimo Triggiani
Discussion
Coffee break
Session 7: Multidisciplinary board on ISM – Phenotype, basic treatment and TKIs
Presentation + discussion in the board with special attention on:
Complexity of clinical phenotype: symptom burden, GI involvement, bone disease by Sigurd Broesby-Olsen
Bare minimum or going the extra mile for diagnosis of SM by Vito Sabato
Strengths and limitations of basic treatment by Friederike Wortmann
Pros and cons TKI treatment by Deepti Radia
Summary by Deepti Radia
Keynote 1:
Introduction by Peter Valent
Diagnosis and therapy of MCAS: status 2026 by Cem Akin
Summary of day 2 and announcements
Peter Valent
Dinner at Luisenpark, Weißer Pavillon, Gartenschauweg 18, 68165 Mannheim
Sponsored by Blueprint
Registration and Welcome
Session 8: Multidisciplinary Board on AdvSM – TKIs and beyond
Presentation + discussion in the board with special attention on:
Treatment indication (which/when/why) by Andreas Reiter
Overview on efficacy of TKI therapy in SM by Jens Panse
Approach to ASM, MCL, MCL-AHN and SM-AML by Olivier Hermine
The dark side of TKI therapy: toxicity, resistance and progression by Juliana Schwaab
The place for allogeneic HCT in the therapeutic algorithm of SM in the TKI era: who and when to transplant? by Deborah Christen
Summary by Jens Panse
Keynote 2:
Introduction by Andreas Reiter
SM in 2026 and future directions by Jason Gotlib
Coffee break
Session 9: Special Issues and disease variants
Chair: Jason Gotlib, Alberto Orfao
Mast cell leukemia and MCL-like cell lines by Michel Arock
Symptom assessment in mastocytosis by Frank Siebenhaar
Smoldering systemic mastocytosis by Wolfgang R. Sperr
KIT D816V negative SM by Iván Alvarez-Twose
Discussion
Lunch break
Session 10: Short communications: hot topics/oral abstracts
Evaluation of Bone Formation Marker Changes in Summit – an exploratory analysis by Boggs
Long term skeletal Outcomes of zoledronate therapy for SM related bone disease reveal different trajectories in patients w/o Anaphylaxis by Aldegheri
Efficacy and Safety of Bezuclastinib in Patients with advanced systemic mastocytosis (Apex) by Radia
Outcomes, leukemic transformation and impact of KIT TKIs in SM-AHN by Rossignol
Modeling Systemic Mastocytosis with AHN: Effects of KITD814V and JAK2V617F in a hematopoietic mouse model by Sheremeti
A roadmap towards Targeting KIT D816V in Mastocytosis with Non-TKI Compounds by Zenke
Mice expressing KITD814V in the Mast cell lineage Show SM Phenotypic skin lesions that can be reversed by TKI treatment by Stivala
Avapritinib improves QOL in ISM – a prospective nationwide real world study by Gourguechon
Clinical manifestations associated with HAT gene dosage, anaphylaxis and SM by Fratessa
Repeated basal serum tryptase elevation is associated with anaphylaxis in pediatric mast cell disorders by Mol
Summary of day 3 and final announcements
Peter Valent
Frank Siebenhaar
Juliana Schwaab
Andreas Reiter
Coffee break
Patient Forum
Chairs: Karin Hartmann, Frank Siebenhaar, Juliana Schwaab, Andreas Reiter, Peter Valent
Impact of SM on QOL and daily life activities Patients Q/A and discussion by Karin Hartmann
Patients´views and recommendations to the scientific community by N. Hegmann / J. Kurz
MASTHAVE APP tools to improve patient-doctor communication by Frank Siebenhaar
Special challenges for patients with mastocytosis by J. Hobarts
Q&A
Register now for the 24th ECNM Annual Meeting and secure your participation in this international scientific event.
